Categories
Change Password!
Reset Password!
GLP-1 RA therapy reduces the risk of incident atrial fibrillation by 46% in patients with HFpEF and HFmrEF while also improving weight, blood pressure, and left atrial remodeling.
As per the findings of a recent study, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may substantially lower the risk of atrial fibrillation (AF) in people with heart failure with preserved ejection fraction (HFpEF) and heart failure with mildly reduced ejection fraction (HfmrEF).
AF is a common complication in HFpEF, linked to increased morbidity and worse clinical outcomes. While GLP-1 RAs are already recognized for their metabolic and cardiovascular benefits, their impact on AF incidence had not been clearly established—until now. Rohanti Ravikulan and other researchers systematically reviewed MEDLINE, Embase, and Cochrane databases, identifying 4 randomized controlled trials—SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM—enrolling 3,743 people with HFpEF or HfmrEF.
In this meta-analysis, GLP-1 RA therapy lowered the risk of new-onset AF by 46% (risk ratio [RR] 0.54), with moderate heterogeneity (I² = 51%). Secondary endpoints portrayed a substantial decrease in systolic blood pressure, body weight, and left atrial volume among those receiving GLP-1 RAs—factors known to contribute to AF development.
These findings suggest that GLP-1 RAs may provide rhythm-protective benefits in addition to their established effects on weight and cardiovascular health. They emphasized the need for dedicated HFpEF trials with adjudicated AF outcomes to confirm these promising results. This research highlights GLP-1 RAs as a potential multi-benefit therapy for HFpEF and HFmrEF patients, offering metabolic, hemodynamic, and now potentially rhythm-modifying advantages.
European Journal of Heart Failure
Glucagon-like peptide-1 receptor agonists reduce atrial fibrillation among patients with heart failure with preserved and mildly reduced ejection fraction - a meta-analysis of randomized controlled trials
Rohanti Ravikulan et al.
Comments (0)